Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EQCVE:GPHNYSE:RGCCVE:WMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEQEquillium$0.35-10.2%$0.41$0.33▼$1.50$12.39M1.94432,887 shs1.11 million shsGPHGraphite OneC$0.77-2.5%C$0.85C$0.55▼C$1.07C$77.97M1.0270,365 shs80,563 shsRGCRegal Entertainment Group$596.11+12,165.6%$0.00$3.03▼$950.00$53.35M-0.59265,941 shs2,031 shsWMDWeedMDC$0.28-1.8%C$0.28C$0.23▼C$0.99C$67.82MN/A766,591 shs271,436 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEQEquillium-10.22%-8.68%-7.05%-54.03%-51.20%GPHGraphite One-2.53%-12.50%-1.28%-20.62%+6.94%RGCRegal Entertainment Group-4.17%-15.19%+55.11%+4,628.40%+12,397.06%WMDWeedMD0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEQEquillium3.1442 of 5 stars3.25.00.00.03.31.70.6GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/ARGCRegal Entertainment Group0.2754 of 5 stars0.05.00.00.00.60.00.0WMDWeedMDN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEQEquillium 2.33Hold$3.00764.55% UpsideGPHGraphite One 0.00N/AN/AN/ARGCRegal Entertainment Group 0.00N/AN/AN/AWMDWeedMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RGC, GPH, WMD, and EQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEQEquillium$30.41M0.41N/AN/A$0.64 per share0.54GPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/ARGCRegal Entertainment GroupN/AN/AN/AN/A$0.63 per shareN/AWMDWeedMDC$27.53M2.46C$0.08 per share3.27C$0.34 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEQEquillium-$13.34M-$0.39N/AN/AN/A-10.05%-20.68%-10.77%8/6/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/ARGCRegal Entertainment Group-$4.30MN/A0.00∞N/AN/AN/AN/AN/AWMDWeedMDN/A-C$0.42N/A∞N/AN/AN/AN/AN/ALatest RGC, GPH, WMD, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEQEquilliumN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/ARGCRegal Entertainment GroupN/AN/AN/AN/AN/AWMDWeedMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEQEquilliumN/A3.043.04GPHGraphite One0.021.090.33RGCRegal Entertainment GroupN/A41.9241.92WMDWeedMD95.633.461.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEQEquillium27.05%GPHGraphite One0.07%RGCRegal Entertainment Group0.13%WMDWeedMDN/AInsider OwnershipCompanyInsider OwnershipEQEquillium31.60%GPHGraphite One28.81%RGCRegal Entertainment Group2.00%WMDWeedMDN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEQEquillium4035.72 million24.70 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableRGCRegal Entertainment GroupN/A13.01 million12.75 millionNot OptionableWMDWeedMD628246.62 millionN/ANot OptionableRGC, GPH, WMD, and EQ HeadlinesRecent News About These CompaniesENTG:CA Entourage Health Corp.October 19, 2024 | seekingalpha.comHurricane Helene by the numbers: Catastrophic destruction covers 400 milesOctober 4, 2024 | abcnews.go.comWMDH WMD Holdings Group, Inc.September 28, 2024 | seekingalpha.comEthics and Weapons of Mass DestructionAugust 8, 2024 | cambridge.org'Truth about WMD will finally emerge'March 4, 2024 | dailymail.co.ukNo cabinet submission on costs, benefits, implications of going to war in IraqJanuary 3, 2024 | theaustralian.com.auBlair: 'Saddam still has weapons of mass destruction'October 5, 2023 | dailymail.co.ukBush administration retreats on WMD claimAugust 29, 2023 | namibian.com.naMissing WMD ‘hurting war on terror’August 29, 2023 | namibian.com.naWeapons of Mass Destruction and the ethics of their usageAugust 17, 2023 | arstechnica.comRussia used sabotaged dam as ‘weapon of mass destruction’ says UkraineJune 12, 2023 | politico.euUS, South Korea issue fresh North Korea sanctions on 'illicit' IT workforceMay 27, 2023 | asahi.comMalaysia Gets Tough on WMDMay 27, 2023 | thediplomat.comInterpol Tackles WMD TerrorismMay 21, 2023 | thediplomat.com'Weapons of mass destruction found'May 20, 2023 | dailymail.co.ukChemical Weapons are NOT WMDsMay 17, 2023 | thediplomat.comThe Next Financial WMD?May 14, 2023 | thestreet.comThe Week in Weed – May 6, 2023 - StratCannMay 6, 2023 | news.google.comWMD in Iraq: Evidence and ImplicationsApril 28, 2023 | medscape.comWhat happened when WMD experts tried to make the GPT-4 AI do bad thingsApril 2, 2023 | thebulletin.orgNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGC, GPH, WMD, and EQ Company DescriptionsEquillium NASDAQ:EQ$0.35 -0.04 (-10.22%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.58%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Graphite One CVE:GPHC$0.77 -0.02 (-2.53%) As of 06/13/2025 01:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.Regal Entertainment Group NYSE:RGCRegal Entertainment Group is an operator of theatre circuits in the United States. As of March 31, 2017, the Company operated 7,262 screens in 559 theatres in 43 states along with Guam, Saipan, American Samoa and the District of Columbia. The Company manages its business under theatre exhibition operations segment. The Company develops, acquires and operates multi-screen theatres primarily in mid-sized metropolitan markets and suburban growth areas of metropolitan markets throughout the United States. The Company operates multi-screen theatres. The Company is the parent company of Regal Entertainment Holdings, Inc. (REH), which is the parent company of Regal Cinemas Corporation (Regal Cinemas) and its subsidiaries. Regal Cinemas' subsidiaries include Regal Cinemas, Inc. (RCI) and its subsidiaries, which include Edwards Theatres, Inc. (Edwards), Regal CineMedia Corporation (RCM) and United Artists Theatre Company (United Artists).WeedMD CVE:WMDC$0.28 -0.01 (-1.79%) As of 07/15/2021WeedMD Inc. produces, distributes, and sells medical-grade cannabis in Canada. It offers dried cannabis, cannabis plants and seeds, cannabis oil, edibles, extracts and topicals, and others, as well as cannabis flower products. The company sells its products directly to medical patients and strategic relationships across the seniors' market, as well as through supply agreements with Shoppers Drug Mart and six provincial distribution agencies under the Color Cannabis, Saturday, Starseed, and WeedMD brand names. WeedMD Inc. is headquartered in Aylmer, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
